Overview

A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing

Status:
Recruiting
Trial end date:
2024-05-24
Target enrollment:
Participant gender:
Summary
Multiple-dose study to measure PK, PD and safety of bempedoic acid in pediatric patients 6 to 17 years of age with HeFH.
Phase:
Phase 2
Details
Lead Sponsor:
Esperion Therapeutics, Inc.
Treatments:
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid